Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 4 study of Fabrazyme in Chinese participants with Fabry disease
2023-000624-11Phase 4
- Sponsor
- Sanofi
- Start
- Jun 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Primary endpoint: Incidence of treatment-emergent adverse events.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2023-000624-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000624-11.